Benzinga  Aug 27  Comment 
Analysts at Jefferies initiated coverage on MannKind (NASDAQ: MNKD) with a Buy rating. The target price for MannKind is set to $10. MannKind shares have jumped 23.99% over the past 52 weeks, while the S&P 500 index has gained 22.66% in the...
SeekingAlpha  Aug 26  Comment 
By Orange Peel Investments: By Parke Shall We think that MannKind (NASDAQ:MNKD) is eventually going to be a long term winner for those holding the stock. Though we rarely get involved with the biotech sector, we've been following the MannKind...
SeekingAlpha  Aug 25  Comment 
By Achilles Research: MannKind's (NASDAQ:MNKD) stock has been in freefall since the end of June and the decline in share price was quite deserved. In fact, I can hardly imagine any other biopharmaceutical company that is as loved as MannKind, even...
SeekingAlpha  Aug 20  Comment 
By George Rho: Developmental-stage biotechnology stocks are by their very nature story stocks, driven by news, hope, fear, hype, uncertainty, emotions, and expectations. Their individual stories will continue as long as there is some underlying...
SeekingAlpha  Aug 18  Comment 
By EnhydrisPECorp: I think of myself as a contrarian investor with a long-term outlook. And for the most part, this approach has served me well over the years. For example, I used some of my earnings from my first job following high school...
Motley Fool  Aug 16  Comment 
Biotech partnerships, an IPO that wasn't, and how big data is fighting Ebola.
SeekingAlpha  Aug 14  Comment 
By Psycho Analyst: Pundits of all stripes are opining about the Mannkind-Sanofi partnership without knowing any of the facts. Many statements being made both by bulls and bears display a lack of understanding of the product itself, its potential...
Motley Fool  Aug 13  Comment 
Quotes from MannKind Corp.'s conference calls.
SeekingAlpha  Aug 13  Comment 
By Jeff Eiseman: The partnership between Sanofi (NYSE:SNY) and MannKind (NASDAQ:MNKD) calls for all of each company's relevant present and prior costs to be counted when calculating net profits. This does not mean, as at least one commenter has...
SeekingAlpha  Aug 13  Comment 
By Trevor Lowenthal: In June, I wrote a bull article on MannKind (NASDAQ:MNKD), with a conservative thesis stating that while regulatory approval for Afrezza was priced into the stock, the company's long-term prospects as an emerging competitor...


MannKind is a biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic products for diabetes, cancer, and inflammatory and autoimmune diseases. The company's lead product, the Technosphere Insulin System, meant for the treatment of diabetes, is in a series of pivotal phase III trial in the U.S. This product utilizes MannKind s proprietary dry powder Technosphere formulation of insulin. It is inhaled deep into the lungs using the company s MedTone inhaler. Besides the company s development of Technosphere, MannKind is pursuing efforts aimed at the discovery and development of novel drugs for metabolic and immunological diseases. The company also has early-stage development programs for the treatment of solid-tumor cancers. MannKind initiated phase I trials with its cancer candidates in early 2007. MannKind's corporate headquarters and immunology research operations are located in Valencia, CA. Significant operations, including the Technosphere Insulin research, development and manufacturing are located in Danbury, CT. The company's initial public offering (IPO) took place in late July 2004.

Business & Financial Metrics[1]

In 2009, MannKind incurred a net loss of $220.1 million and reported no revenue. This represents a 27.4% reduction in net loss from 2008, when the company lost $303.0 million. Since its inception in 1991, MannKind has lost $1.60 billion and generated $3.0 million in revenues.


MannKind's primary competitors include:


  1. MNKD 2009 10-K pg. 64  
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki